{"entity":{"id":"nct04014205","kind":"trial","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","aka":[],"tldr":"A phase 1/2 trial of Orelabrutinib in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., active and no longer recruiting.","summary":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies is a phase 1/2 interventional study registered as NCT04014205 by Beijing InnoCare Pharma Tech Co., Ltd., with 81 participants enrolled, started 2019-11-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: Orelabrutinib (ICP-022).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04014205","url":"https://clinicaltrials.gov/study/NCT04014205"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["orelabrutinib"],"companies":["innocare"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04014205","phase":"1/2","setting":"A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","started":"2019-11-18","startedType":"actual","enrolled":81,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04014205/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/"}],"company":[{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/"}]}}